The prestigious award in Physiology or Medicine has been granted for transformative findings that clarify how the immune system targets harmful infections while protecting the body's own cells.
A trio of esteemed scientists—Japan's Shimon Sakaguchi and US experts Dr. Brunkow and Fred Ramsdell—received this accolade.
Their work uncovered unique "security guards" within the immune system that eliminate rogue immune cells that could harming the body.
The discoveries are now paving the way for innovative treatments for immune disorders and cancer.
The laureates will divide a prize fund valued at 11 million Swedish kronor.
Decisive Discoveries
"Their work has been essential for comprehending how the immune system functions and why we do not all develop serious autoimmune diseases," stated the chair of the Nobel Committee.
This team's studies address a fundamental question: In what way does the immune system defend us from countless infections while keeping our healthy cells intact?
The body's protection system employs white blood cells that scan for signs of disease, even viruses and germs it has never encountered.
These cells utilize detectors—called receptors—that are produced randomly in countless combinations.
This gives the defense network the capacity to fight a wide array of threats, but the unpredictability of the process unavoidably creates immune cells that may target the host.
Security Guards of the Immune System
Researchers earlier understood that some of these problematic white blood cells were eliminated in the thymus—the site where white blood cells develop.
This year's Nobel Prize honors the identification of regulatory T-cells—known as the body's "security guards"—which patrol the system to disarm any immune cells that attack the healthy cells.
We know that this mechanism fails in self-attack conditions such as type-1 diabetes, multiple sclerosis, and rheumatoid arthritis.
The prize committee stated, "These discoveries have laid the foundation for a new field of research and spurred the creation of new therapies, for instance for tumors and autoimmune diseases."
In malignancies, T-regs block the system from fighting the growth, so research are focused on reducing their quantity.
For autoimmune diseases, trials are exploring boosting T-reg cells so the organism is no longer under attack. A comparable approach could also be effective in minimizing the chances of transplanted organ rejection.
Pioneering Studies
Professor Sakaguchi, from Osaka University, conducted experiments on mice that had their immune gland extracted, leading to self-attack conditions.
The researcher showed that injecting defense cells from other animals could stop the disease—suggesting there was a system for preventing immune cells from attacking the host.
Dr. Brunkow, affiliated with the a research center in Seattle, and Fred Ramsdell, currently at Sonoma Biotherapeutics in San Francisco, were investigating an genetic immune disorder in mice and people that led to the discovery of a gene critical for the way T-regs operate.
"Their pioneering research has uncovered how the body's defenses is kept in check by T-reg cells, stopping it from mistakenly targeting the healthy cells," said a prominent biological science expert.
"The research is a striking illustration of how basic biological study can have broad implications for public health."
